摘要
目的:观察曲美他嗪联合比索洛尔治疗高血压心肌肥厚患者的效果。方法:选取70例高血压心肌肥厚患者为研究对象,按照随机数字表法分为对照组与观察组各35例。对照组口服比索洛尔,观察组在对照组基础上加用曲美他嗪,比较两组治疗前后炎性因子水平、心肌重构指标水平及不良反应发生率。结果:治疗后,两组炎性因子水平和心肌重构指标水平均低于治疗前,且观察组明显低于对照组,差异有统计学意义(P<0.05);两组均未发生明显不良反应。结论:曲美他嗪联合比索洛尔治疗高血压心肌肥厚患者可降低血清炎性因子水平和心肌重构指标水平,效果优于单纯比索洛尔治疗效果。
Objective:To investigate effects of Trimetazidine combined with Bisoprolol on levels of serum inflammatory factors and myocardial remodeling indexes for patients with hypertensive myocardial hypertrophy.Methods:70 patients with hypertensive myocardial hypertrophy were selected as the research objects,and were divided into control group and observation group according to the random number table method,35 cases in each group.The control group was given Bisoprolol orally,while the observation group was given Trimetazidine on the basis of that of the control group.Then,the levels of inflammatory factors and ventricular structure indexes as well as the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of inflammatory factors and myocardial remodeling indexes in the two groups were lower than those before the treatment;those of the observation group were significantly lower than those of the control group;and the differences were statistically significant(P<0.05).No obvious adverse reactions occurred in the two groups.Conclusions:Trimetazidine combined with Bisoprolol in the treatment of hypertensive myocardial hypertrophy can reduce the serum inflammatory factor levels and myocardial remodeling index levels.Moreover,it is superior to single Bisoprolol.
作者
徐晶
XU Jing(Department of Pharmacy of Pingdingshan People’s Hospital No.1,Pingdingshan 467000 Henan,China)
出处
《中国民康医学》
2020年第13期9-11,共3页
Medical Journal of Chinese People’s Health
关键词
高血压心肌肥厚
比索洛尔
曲美他嗪
炎性因子
心肌重构
Hypertensive cardiac hypertrophy
Bisoprolol
Trimetazidine
Inflammatory factor
Myocardial remodeling
